[{"id":"a79e3a47-2879-4f52-9a2b-1758c599f498","acronym":"RPO-S+","url":"https://clinicaltrials.gov/study/NCT03121469","created_at":"2021-01-18T15:22:45.733Z","updated_at":"2025-02-25T14:01:17.226Z","phase":"","brief_title":"Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer","source_id_and_acronym":"NCT03121469 - RPO-S+","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression + HR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-19"},{"id":"f65dd733-9008-4681-bf13-626c30073cdc","acronym":"SAFIR 03","url":"https://clinicaltrials.gov/study/NCT05625087","created_at":"2022-11-22T15:59:03.927Z","updated_at":"2025-02-25T15:54:42.995Z","phase":"Phase 2","brief_title":"Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib","source_id_and_acronym":"NCT05625087 - SAFIR 03","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 overexpression • HER-2 negative • PIK3CA mutation • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • triptorelin"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 10/19/2023","start_date":" 10/19/2023","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-01-30"},{"id":"c1de4320-1800-4ab1-8b43-eb87d669c526","acronym":"","url":"https://clinicaltrials.gov/study/NCT01730833","created_at":"2021-01-18T07:33:38.779Z","updated_at":"2025-02-25T12:25:57.142Z","phase":"Phase 2","brief_title":"Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer","source_id_and_acronym":"NCT01730833","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 amplification + HR-positive • HER-2 overexpression + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 07/17/2013","start_date":" 07/17/2013","primary_txt":" Primary completion: 01/12/2021","primary_completion_date":" 01/12/2021","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-15"}]